Galcanezumab - CISMeF

Preferred Label : Galcanezumab;

NCIt synonyms : Galcanezumab-gnlm;

NCIt related terms : Emgality;

NCIt definition : A humanized immunoglobulin G4 (IgG4) monoclonal antibody targeting calcitonin-gene related peptide (CGRP) ligand, that can be used in the preventive treatment of migraine. Upon subcutaneous administration, galcanezumab specifically targets and binds to CGRP ligand, and blocks the binding of the CGRP ligand to its receptor. This blocks the CGRP pathway and prevents migraine.;

UNII : 55KHL3P693;

CAS number : 1578199-75-3;

Drug name : Emgality;

NCI Metathesaurus CUI : CL971810;

Détails

Origin ID

C166816;

UMLS CUI

C4694273;

Currated CISMeF NLP mapping
- Galcanezumab [Anticorps monoclonal]
- Galcanezumab [ICD-11 Extension code]
- Galcanezumab [SMS substance]
- Galcanezumab (substance) [SNOMED CT concept]
- galcanezumab [MeSH concept]
- galcanezumab [MeSH Supplementary Concept]
See also inter- (CISMeF)
- Product containing galcanezumab (medicinal product) [SNOMED CT concept]
Semantic type(s)
- Amino Acid, Peptide, or Protein [UMLS semantic type]
- Immunologic Factor [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Galcanezumab (substance) [SNOMED CT concept]
- Product containing galcanezumab (medicinal product) [SNOMED CT concept]
- galcanezumab [ATC Code]
- galcanezumab [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- galcanezumab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- FDA Established Names and Unique Ingredient Identifier Codes Terminology [NCIt concept]

Position du mot-clé dans l'(les) arborescence(s) :

Vous pouvez consulter :

recommendations
documents concerning education
documents for patients